Moreover, an increased ratio of the TIGIT/DNAM-1 expression on tumor-infiltrating Tregs is related to a high percentage of Tregs in melanoma patients treated with mAbs targeted against PD-1 and/or CTLA-4. Here, CD226 is linked to melanoma.